drugset / Trial / NCT01603043

A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)

NCT01603043

Phase 2 Terminated 10 enrolled Alcon Research
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.

Timeline

Start
2012-06
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AL-78898A Unknown 0.4 mg Intravitreal